| CLS-positive n (%) | CLS-negative n (%) |  | Unadjusted | Adjustedb | ||
---|---|---|---|---|---|---|---|
Patient characteristic | p valuea | OR | 95% CI | OR | 95% CI | ||
Age | Â | Â | 0.30 | Â | Â | Â | Â |
 40–49 years | 1 (3.3) | 7 (13.0) |  | 0.34 | 0.04–3.20 | 0.31 | 0.03–3.12 |
 50–59 years | 8 (26.7) | 19 (35.2) |  | Reference | Reference | ||
 60–69 years | 12 (40.0) | 18 (33.3) |  | 1.68 | 0.55–5.08 | 1.17 | 0.35–3.91 |
 ≥70 years | 9 (30.0) | 10 (18.5) |  | 2.14 | 0.63–7.26 | 1.63 | 0.45–6.00 |
BMI category | Â | Â | 0.03 | Â | Â | Â | Â |
 Lean | 4 (14) | 19 (36) |  | Reference | Reference | ||
 Overweight | 13 (43) | 23 (43) |  | 2.69 | 0.75–9.61 | 1.93 | 0.50–7.40 |
 Obese | 13 (43) | 11 (21) |  | 5.61 | 1.46–21.53 | 4.63 | 1.08–19.83 |
Age at menarche | Â | Â | 0.28 | Â | Â | Â | Â |
 <13 years | 9 (31) | 10 (19) |  | Reference | Reference | ||
 ≥13 years | 20 (69) | 43 (81) |  | 0.52 | 0.18–1.47 | 0.40 | 0.12–1.32 |
Age at menopause | Â | Â | 0.09 | Â | Â | Â | Â |
 <45 years | 2 (7) | 6 (11) |  | Reference | Reference | ||
 45–49 years | 8 (27) | 25 (47) |  | 0.96 | 0.16–5.74 | 1.50 | 0.21–10.44 |
 50–54 years | 13 (43) | 18 (34) |  | 2.17 | 0.38–12.50 | 2.95 | 0.42–20.68 |
 ≥55 years | 7 (23) | 4 (8) |  | 5.25 | 0.70–39.48 | 6.19 | 0.63–60.73 |
Age at first birth | Â | Â | 1.00 | Â | Â | Â | Â |
 Nulliparous | 5 (17) | 10 (19) |  | Reference | Reference | ||
 <30 years | 20 (66) | 35 (66) |  | 1.14 | 0.34–3.82 | 1.08 | 0.28–4.17 |
 ≥30 years | 5 (17) | 8 (15) |  | 1.25 | 0.27–5.89 | 1.42 | 0.26–7.93 |
Family history of breast cancer | Â | Â | 0.53 | Â | Â | Â | Â |
 No | 24 (80) | 46 (87) |  | Reference | Reference | ||
 Yes | 6 (20) | 7 (13) |  | 1.64 | 0.50–5.44 | 2.91 | 0.71–11.96 |
Benign breast disease | Â | Â | 0.74 | Â | Â | Â | Â |
 No | 25 (89) | 44 (85) |  | Reference | Reference | ||
 Yes | 3 (11) | 8 (15) |  | 0.66 | 0.16–2.72 | 1.09 | 0.22–5.35 |
Tumor size | Â | Â | 1.00 | Â | Â | Â | Â |
 ≤2 cm | 15 (52) | 26 (49) |  | Reference | Reference | ||
 >2 cm | 14 (48) | 27 (51) |  | 0.90 | 0.36–2.22 | 0.62 | 0.22–1.75 |
Nodal status | Â | Â | 0.22 | Â | Â | Â | Â |
 No | 20 (67) | 26 (49) |  | Reference | Reference | ||
 1–3 | 7 (23) | 15 (28) |  | 0.61 | 0.21–1.77 | 0.38 | 0.11–1.41 |
 ≥4 | 3 (10) | 12 (23) |  | 0.33 | 0.08–1.31 | 0.44 | 0.10–2.00 |
ER status | Â | Â | 0.80 | Â | Â | Â | Â |
 Positive | 21 (70) | 39 (74) |  | Reference | Reference | ||
 Negative | 9 (30) | 14 (26) |  | 1.19 | 0.44–3.22 | 1.09 | 0.35–3.39 |
PR status | Â | Â | 0.80 | Â | Â | Â | Â |
 Positive | 21 (70) | 39 (74) |  | Reference | Reference | ||
 Negative | 9 (30) | 14 (26) |  | 1.19 | 0.44–3.22 | 1.09 | 0.35–3.39 |
Diagnosis | Â | Â | 0.65 | Â | Â | Â | Â |
 In situ and invasive | 17 (57) | 33 (62) |  | Reference | Reference | ||
 Invasive only | 13 (43) | 20 (38) |  | 1.26 | 0.51–3.14 | 1.22 | 0.45–3.29 |
Grade | Â | Â | 0.70 | Â | Â | Â | Â |
 Well differentiated | 4 (13) | 11 (21) |  | Reference | Reference | ||
 Moderately differentiated | 19 (64) | 29 (55) |  | 1.80 | 0.50–6.49 | 1.32 | 0.33–5.24 |
 Poorly differentiated | 7 (23) | 13 (24) |  | 1.48 | 0.34–6.42 | 1.68 | 0.33–8.55 |